Clinical trials: neoadjuvant therapy, completed
Breast Cancer
A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer
To study the maximum tolerated dose of Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide and sequential treatment of docetaxel for patients with locally advanced breast cancer
- Trial name
- NCT03017404
- Testing
- Doxorubicin Hydrochloride Liposome Injection, Cyclophosphamide, docetaxel
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Medical University Fourth Hospital
Breast Cancer
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
This study will evaluate the efficacy and safety of treatment with oral capecitabine or intravenous (IV) 5-fluorouracil (5-FU), in combination with epirubicin and cyclophosphamide, prior to surgery in participants with breast…
- Trial name
- NCT02846428
- Testing
- 5-Fluorouracil, Capecitabine, Cyclophosphamide
- Where
- 21 sites in France
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer
Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MR
Treatment of localized muscle invasive bladder cancer (MIBC) is radical cystectomy. Neoadjuvant chemotherapy (NAC) improves survival.
- Trial name
- MAINTAIN (NCT04321707)
- Testing
- 15O-H2O PET/MR
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Jørgen Bjerggaard Jensen
Breast Cancer
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
RATIONALE: Vaccines made from peptides and a person's white blood cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00107211
- Testing
- therapeutic autologous dendritic cells, conventional surgery, neoadjuvant therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colon Cancer, Primary Tumour
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
The clinical benefit of resection of the primary tumour in patients with synchronous unresectable metastases is not known. In the literature studies usually describe retrospective selected patients with synchronous metastases…
- Conditions
- Colon Cancer, Primary Tumour, Rectal Cancer
- Trial name
- CAIRO4 (NCT01606098)
- Testing
- Surgery of the primary tumour, Systemic treatment
- Where
- 46 sites in Denmark, Netherlands
- Volunteers
- 206 people
- Sponsor
- Dutch Colorectal Cancer Group
Breast Cancer
Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer
Explore the efficacy and safety of the combination of inetetamab, pyrotinib and nab-paclitaxel in the neoadjuvant treatment of HER2 positive early or locally advanced breast cancer
- Trial name
- NCT05444998
- Testing
- Inetetamab, pyrotinib, nab-paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen…
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT02003209
- Testing
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Oral Cavity
Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers
Oral cancer is the single largest cancer in males in India. 90-95% cases of oral cancer are Squamous cell carcinomas and many of them present at late stages (T3 and above).
- Trial name
- NCT03923998
- Testing
- Neoadjuvant chemotherapy, Neoadjuvant radiotherapy, Resection and reconstruction
- Where
- India
- Volunteers
- 8 people
- Sponsor
- Indrayani Hospital and Cancer Institute
HER2 Negative Breast Cancer
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced…
- Trial name
- NCT01527487
- Testing
- Eribulin, Cyclophosphamide, Docetaxel
- Where
- 15 sites in United States
- Volunteers
- 76 people
- Sponsor
- SCRI Development Innovations, LLC
Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma
OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma
Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy…
- Conditions
- Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OPPOSITE (NCT03429816)
- Testing
- Biopsy
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Heidelberg
Breast Cancer
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
- Trial name
- NCT00255463
- Testing
- Anastrazole, Gefitinib
- Where
- 34 sites in Czechia, France and 5 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Pancreas Neoplasm Malignant Resectable
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
- Trial name
- NCT02243358
- Testing
- Folfox6, Gemcitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Henry Ford Health System
Prostate Cancer
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using toremifene may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00020735
- Testing
- toremifene, conventional surgery, neoadjuvant therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Joel Nelson, MD
Unresectable Malignant Neoplasm, Melanoma
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body.
- Conditions
- Unresectable Malignant Neoplasm, Melanoma, Metastatic Melanoma, Stage IV Melanoma
- Trial name
- NeoPembroMel (NCT02306850)
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Louis University
Locally Advanced Rectal Cancer, Abdominoperineal Resection
Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
The intention of the study is to explore metabolic and inflammatory parameters in the pelvis after abdominoperineal resection for locally advanced rectal cancer in patients that have received radiation therapy before surgery.
- Conditions
- Locally Advanced Rectal Cancer, Abdominoperineal Resection, Infection
- Trial name
- NCT03392584
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Pancreatic Cancer
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335543
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 254 people
- Sponsor
- Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Breast Cancer
DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating how well patients with breast cancer respond to…
- Trial name
- ACRIN6698 (NCT01564368)
- Testing
- diffusion-weighted magnetic resonance imaging
- Where
- 7 sites in United States
- Volunteers
- 406 people
- Sponsor
- American College of Radiology Imaging Network
Rectal Cancer, Locally Advanced Rectal Carcinoma
MRI T1 Relaxation Time in Rectal Cancer
The goal of this observational study is to learn about the T1 relaxation time and T1 relaxation time properties of the disease in people with locally advanced rectal cancer.
- Trial name
- NCT05876026
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Vejle Hospital
Bladder Cancer, Adult Solid Tumor
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical…
- Trial name
- NCT06059547
- Testing
- Nivolumab, Visugromab (CTL-002)
- Where
- 4 sites in Italy
- Volunteers
- 31 people
- Sponsor
- CatalYm GmbH
Prostate Cancer
Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated
The main purpose of study is to compare the effectiveness of Hypofractionated IMRT boost Radiotherapy to Conventional IMRT boost Radiotherapy for high-risk prostate cancer patients combined with Androgen Deprivation Therapy.
- Trial name
- HYPOPROST (NCT02300389)
- Testing
- Hypofractionated IMRT boost radiotherapy, Conventional Fractionated IMRT boost radiotherapy
- Where
- 3 sites in Poland
- Volunteers
- 288 people
- Sponsor
- The Greater Poland Cancer Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.